Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

Researchers at Rutgers University have created a new antiviral drug for COVID-19 that could be safer and more effective than Paxlovid, the current leading treatment. The new drug, called Jun13296, may ...

Clinical trials moved quickly, and by the end of the year we had the very first oral COVID antiviral ... The result was a medicine called Paxlovid. But as with many things developed quickly ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Pfizer's Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the FDA, as the US braces itself for a surge in Omicron cases over the holiday period.

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. As with its ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Long COVID is arguably the most significant hangover from the pandemic. Here's what has been learned, and what remains ...